Lilly Partners with Creyon Bio in $1B+ Deal to Develop AI-Designed RNA Therapies
Key Insights
Eli Lilly and Creyon Bio (search) have entered a global licensing and multi-target research collaboration worth potentially over $1 billion to develop RNA-targeted oligonucleotide (search) therapies for various diseases.
Creyon Bio (search) will receive $13 million upfront, including cash and equity purchase, and will apply its AI-Powered Oligo Engineering Engine (search) to design drug candidates for Lilly's targets on accelerated timelines.
The partnership aims to create safer and more effective therapies by using quantum chemistry principles rather than traditional trial-and-error screening, representing a significant advancement in nucleic acid drug development.
Eli Lilly and Company has formed a strategic partnership with San Diego-based Creyon Bio (search) to discover, develop, and commercialize novel RNA-targeted oligonucleotide (search) therapies across a broad spectrum of diseases. The collaboration, announced on April 29, 2025, could potentially exceed $1 billion in value and comes less than a week after Creyon appointed new leadership.
Under the terms of the agreement, Creyon will receive an upfront payment of $13 million, which includes cash and the purchase of Creyon equity. The biotech company stands to earn over $1 billion in additional development and commercialization milestone payments. Lilly will gain exclusive licensing rights to lead candidates for each target and will assume responsibility for further research, development, and commercialization after certain milestones are achieved.
AI-Powered Approach to Oligonucleotide Development
The partnership will leverage Creyon's proprietary AI-Powered Oligo Engineering Engine (search), which the company describes as an "industry-first" technology that significantly accelerates development timelines for RNA-targeted therapies.
"Creyon has built an industry-first and only oligo engineering engine to efficiently design RNA-targeted oligo therapies using quantum chemistry principles rather than relying on traditional trial-and-error screening processes to significantly accelerate development timelines," explained Swagatam Mukhopadhyay, Co-Founder and Chief Innovation Officer at Creyon Bio (search).
This computational approach represents a paradigm shift in oligonucleotide drug development, moving away from conventional screening methods toward a more systematic and predictive design process. The technology aims to optimize both safety and efficacy parameters from the earliest stages of drug candidate selection.
Strategic Significance for Both Companies
For Creyon Bio (search), this partnership marks a significant milestone in its corporate development, particularly following recent leadership changes. Serge Messerlian, who was recently appointed as Chairman and Chief Executive Officer of Creyon Bio, emphasized the importance of the collaboration.
"We are pleased to partner with Lilly to advance our AI-designed oligos with the goal of making therapies safer and more effective for patients. This partnership marks an important milestone for Creyon as we work to advance our RNA-targeted oligo therapy pipeline to the clinic for both rare and common diseases," said Messerlian.
The deal aligns with Lilly's growing interest in RNA-targeted therapeutics, an area that has gained substantial momentum across the pharmaceutical industry in recent years. By partnering with Creyon, Lilly gains access to specialized technology that could potentially accelerate its entry into this therapeutic space.
Advancing Oligonucleotide Therapeutics
Oligonucleotide therapeutics represent a growing class of drugs that can selectively target RNA to modulate gene expression or protein production. These therapies have shown promise for treating previously undruggable targets and addressing both rare genetic disorders and more common conditions.
Creyon Bio (search)'s approach combines computational methods with aptamer-based, tissue-specific delivery approaches to develop oligonucleotide therapies with improved targeting capabilities. This dual focus on both drug design and delivery addresses two critical challenges in the field: creating oligonucleotides with optimal activity and ensuring they reach the intended tissues.
The collaboration between Lilly and Creyon Bio (search) reflects the pharmaceutical industry's increasing investment in AI-driven drug discovery platforms, particularly for complex modalities like oligonucleotide therapeutics. By combining Lilly's development expertise and commercial capabilities with Creyon's specialized technology platform, the partnership aims to accelerate the path to clinic for novel RNA-targeted therapies.
While specific disease targets have not been disclosed, the agreement encompasses a broad range of potential indications, including both rare and common diseases, suggesting a comprehensive approach to exploring the therapeutic potential of this technology platform.